Pigs said: "It is possible sales will fall to almost zero if better or cheaper alternatives are available. That is how the pharmaceutical industry works."
The pharma industry works on facts not fantasy and that is a fact. The fact is there is no better alternative available and for at least a decade there is not likely to be. The only potential competitor is definitely not better and has many hurdles to climb if they are even to become a competitor such as trials to complete, SAFETY questions to overcome, regulators to deal with, approval to gain, insurers and experts to convince and so on. Then after all that, if they do enter the market, they will be competing with Clinuvels drug which has proven life changing for EPP patients, is SAFE, has other benefits like aiding liver function and circadian rhythms and soon will be shown to assist DNA Repair. So which drug would a physician prescribe and a patient want? Even you Pigs would find the answer to that a simple one.
Clinuvel has more approved products than most peer biotechs who have higher valuations and they have better financials than any peer biotech. The price is suppressed largely due to the fake liquidity created by Shorting, more than 5% of fake shares sold into the market has created an imbalance and they have been sold with the intention to drive the price down. CUV has a monopoly and will have for years to come and they are growing revenue and profits by more than 50% yoy while advancing their clinical programs in mega indications. Those are the facts, the recent quarterly report proved it and the half yearly report in 3 weeks will prove it again.
All IMO DYOR
- Forums
- ASX - By Stock
- Clinuvel compared to Imugene
CUV
clinuvel pharmaceuticals limited
Add to My Watchlist
1.84%
!
$10.16

Pigs said: "It is possible sales will fall to almost zero if...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$10.16 |
Change
-0.190(1.84%) |
Mkt cap ! $509.2M |
Open | High | Low | Value | Volume |
$10.35 | $10.44 | $10.15 | $621.4K | 60.52K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2039 | $10.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$10.17 | 124 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1094 | 10.150 |
1 | 2000 | 10.140 |
1 | 110 | 10.100 |
1 | 1000 | 10.090 |
1 | 1000 | 10.080 |
Price($) | Vol. | No. |
---|---|---|
10.200 | 1995 | 1 |
10.290 | 30 | 1 |
10.500 | 100 | 1 |
10.570 | 1000 | 1 |
10.600 | 100 | 1 |
Last trade - 16.13pm 04/07/2025 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online